



UNIL | Université de Lausanne

Unicentre

CH-1015 Lausanne

<http://serval.unil.ch>

Year : 2022

Utility of polymerase chain reaction in nasopharyngeal swabs for identifying respiratory bacteria causing community-acquired pneumonia

Demars Yoris Orion

Demars Yoris Orion, 2022, Utility of polymerase chain reaction in nasopharyngeal swabs for identifying respiratory bacteria causing community-acquired pneumonia

Originally published at : Thesis, University of Lausanne

Posted at the University of Lausanne Open Archive <http://serval.unil.ch>

Document URN : urn:nbn:ch:serval-BIB_C7B94EC479FE8

Droits d'auteur

L'Université de Lausanne attire expressément l'attention des utilisateurs sur le fait que tous les documents publiés dans l'Archive SERVAL sont protégés par le droit d'auteur, conformément à la loi fédérale sur le droit d'auteur et les droits voisins (LDA). A ce titre, il est indispensable d'obtenir le consentement préalable de l'auteur et/ou de l'éditeur avant toute utilisation d'une oeuvre ou d'une partie d'une oeuvre ne relevant pas d'une utilisation à des fins personnelles au sens de la LDA (art. 19, al. 1 lettre a). A défaut, tout contrevenant s'expose aux sanctions prévues par cette loi. Nous déclinons toute responsabilité en la matière.

Copyright

The University of Lausanne expressly draws the attention of users to the fact that all documents published in the SERVAL Archive are protected by copyright in accordance with federal law on copyright and similar rights (LDA). Accordingly it is indispensable to obtain prior consent from the author and/or publisher before any use of a work or part of a work for purposes other than personal use within the meaning of LDA (art. 19, para. 1 letter a). Failure to do so will expose offenders to the sanctions laid down by this law. We accept no liability in this respect.



UNIL | Université de Lausanne

Faculté de biologie
et de médecine

UNIVERSITÉ DE LAUSANNE - FACULTÉ DE BIOLOGIE ET DE MÉDECINE

Département Médecine

Service DES MALADIES INFECTIEUSES

Utility of polymerase chain reaction in nasopharyngeal swabs for identifying
respiratory bacteria causing community-acquired pneumonia

THESE

préparée sous la direction du Docteur Noémie Boillat-Blanco,
avec la co-direction du Professeur Thierry Calandra

et présentée à la Faculté de biologie et de médecine de
l'Université de Lausanne pour l'obtention du grade de

DOCTEUR EN MEDECINE

par

Yoris Orion Demars

Médecin diplômé(e) de la Confédération Suisse
Originaire de Lausanne (Vaud)

Lausanne
2022

Imprimatur

Vu le rapport présenté par le jury d'examen, composé de

Directeur.trice de thèse

Dre Noémie Boillat Blanco

Co-Directeur.trice de thèse

Prof. Thierry Calandra

Expert.e

Dr Benoît Guery

**Vice-Directeur de l'Ecole
doctorale**

Prof. John Prior

la Commission MD de l'Ecole doctorale autorise l'impression de la thèse de


Monsieur Yoris Demars

intitulée

***Utility of polymerase chain reaction in nasopharyngeal
swabs for identifying respiratory bacteria
causing community-acquired pneumonia***

Lausanne, le 29 septembre 2022

*pour Le Doyen
de la Faculté de Biologie et de Médecine*


**Monsieur le Professeur John Prior
Vice-Directeur de l'Ecole doctorale**



Utility of Polymerase Chain Reaction in Nasopharyngeal Swabs for Identifying Respiratory Bacteria Causing Community-Acquired Pneumonia

Yoris Demars,^a Thomas Brahier,^a David C. Rotzinger,^c René Brouillet,^b Katia Jaton,^b Onya Opota,^b Noémie Boillat-Blanco^a

^aInfectious Diseases Service, University Hospital and University of Lausanne, Lausanne, Switzerland

^bInstitute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland

^cDepartment of Diagnostic and Interventional Radiology, University Hospital and University of Lausanne, Lausanne, Switzerland

ABSTRACT Timely identification of a pathogen in lower respiratory tract infections (LRTI) can support appropriate antibiotics use. The difficulty of obtaining lower respiratory tract (LRT) samples limits the utility of point-of-care syndromic molecular assays. We assessed the performance of the FilmArray Pneumonia plus panel (FilmArray PP) in nasopharyngeal (NP) swab for detection of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. Patients in the study included retrospectively consenting adults who attended the emergency department of Lausanne University Hospital between February 2019 and August 2020 for a community-acquired LRTI, with available NP swab and a high-quality LRT sample. These samples were tested with the FilmArray PP (cutoff of $\geq 10^4$ copies/mL). Positive (PPA) and negative percent agreement (NPA) of FilmArray PP in NP swab were calculated, using (i) FilmArray PP in LRT sample and (ii) standard microbiological tests as reference standards. To assess the performance of a lower detection cutoff, NP samples were also tested with an in-house PCR (cutoff of ≥ 10 copies/mL) for *S. pneumoniae* and *H. influenzae*. Overall, 118 patients were included. FilmArray PP in LRT sample and standard microbiology tests detected *S. pneumoniae* in 19/118 and 12/118, *H. influenzae* in 44/118 and 19/118, and *M. catarrhalis* in 14/118 and 0/118, respectively. Using LRT FilmArray PP as reference, PPA and NPA of FilmArray PP on NP were 58% and 100% for *S. pneumoniae*, 61% and 100% for *H. influenzae*, and 57% and 99% for *M. catarrhalis*. Using standard diagnostic tests as reference, PPA and NPA were 58% and 96% for *S. pneumoniae*, 74% and 87% for *H. influenzae*, and indefinite and 92% for *M. catarrhalis*. Using a lower cutoff on NP ($\geq 10^2$ copies/mL), PPA was 68% for *S. pneumoniae* and 77% for *H. influenzae* with LRT FilmArray PP as reference. FilmArray PP in NP swabs has a limited PPA for identifying the most common etiologies of community-acquired LRTI irrespective of the reference standard, preventing its use for withholding antibiotics. The PCR detection cutoff does not explain the low PPA. The excellent NPA suggests the use of NP PCR results for rapidly targeted antimicrobial therapy.

IMPORTANCE Timely identification of a pathogen in patients with lower respiratory tract infections is of paramount importance to avoid inappropriate antibiotic prescription. We aimed to evaluate the performance of a rapid syndromic molecular assay in nasopharyngeal swabs for identifying the most common bacterial causes of lower respiratory tract infections in adults (*Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*). Our data show that nasopharyngeal molecular assay has a good concordance with lower respiratory tract sample when positive but not when negative. A positive result is therefore concordant with a lower respiratory tract infection and can be used to target antibiotics. Nevertheless, a negative result does not have a good concordance, so it cannot be used to withhold antibiotics.

Editor Wendy A. Szymczak, Montefiore Medical Center and Albert Einstein College of Medicine

Copyright © 2022 Demars et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Yoris Demars, yoris.demars@chuv.ch.

The authors declare no conflict of interest.

Received 2 February 2022

Accepted 12 April 2022

Our findings illustrate the potential utility of these easily collected samples for the management of patients with lower respiratory tract infections.

KEYWORDS FilmArray, *Haemophilus influenzae*, *Moraxella catarrhalis*, NP, PCR, POCT, *Streptococcus pneumoniae*, diagnostics, molecular diagnostics, pneumonia

Lower respiratory tract infections (LRTIs) are one of the most common motives to attend emergency departments (ED) and the main reason for inappropriate antibiotic prescription (1). Timely identification of a pathogen in patients with LRTIs may support optimization of antibiotics use.

However, current microbiological methods identify a pathogen in only 40 to 60% of patients with LRTI (2–4) and rely mainly on culture, which is a slow process (5). Rapid syndromic molecular assays targeting respiratory bacteria and viruses are now available (6). Their use in lower respiratory tract (LRT) samples increases pathogen detection to 83 to 87% of patients with LRTI (7, 8), suggesting their utility to deescalate or discontinue antibiotics (7–11). However, less than 50% of the patients produce sputa (12), limiting the impact of using these rapid syndromic molecular assays. Nasopharyngeal (NP) swabs are easy to obtain in all patients and may replace LRT samples, as it has been supposed that LRTIs could be provoked by an organism in the nasopharynx that spread in the lower tract (13). Although molecular tests in NP swabs are accepted for viruses and atypical bacteria such as *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* (14), few studies evaluated their performance on upper respiratory tract samples (URT) for the most common bacterial causes of community-acquired LRTIs, such as *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis*. Four studies evaluated identification of *S. pneumoniae* by real-time PCR (RT-PCR) in NP specimen of patients with community-acquired pneumonia (CAP) with negative percent agreements (NPA) of >90% but with wide differences in positive percent agreement (PPA; 35% to 82%) using standard microbiological tests as gold standard (15–18). No study evaluated the validity of PCR in the NP swabs for other bacteria. To our knowledge, only two studies assessed the performance of a syndromic molecular assay including community-acquired bacteria on URT samples (NP and oropharyngeal [OP] swabs), and they gave contradictory results, as one concluded that sputum was more reliable than NP/OP (19), while the other concluded that sputum had no advantage to detect a pathogen over URT samples (20).

Our study aims to define the performance of the FilmArray Pneumonia plus panel (FilmArray PP) in NP swabs for identifying the most common bacterial causes of LRTIs (*S. pneumoniae*, *H. influenzae*, *M. catarrhalis*) in adults using (i) FilmArray PP in LRT sample and (ii) standard microbiological tests as reference standards. Our study also aims to test the performance of different PCR threshold cutoffs on NP swabs.

RESULTS

Among 1,848 patients (350 during phase 1 and 1,498 during phase 2) eligible with NP swab and LRT samples available, 1,708 (92%) were excluded (1,019 had a poor-quality LRT sample, 276 a sample collected more than 48 h from admission or with ≥ 24 h between NP swab and LRT sample, 163 were hospitalized in an acute care hospital in the last 3 months, 183 did not have an acute LRTI, 39 had bronchiectasis, 16 had cystic fibrosis, and 12 refused to participate). After excluding 22 patients because we did not find their samples, our study population consisted of 118 patients (27 from phase 1 and 91 from phase 2) (Fig. 1).

Patient characteristics. Median age was 71 years (interquartile range [IQR], 56 to 78), 43 (36%) patients were female, and 34 (29%) had chronic obstructive pulmonary disease (COPD) (Table 1). Overall, 88 (75%) had an infiltrate on chest X-ray or CT scan. A total of 108 (96%) patients received an antibiotic, which was started before collecting the LRT sample in 55 (47%) patients. A total of 97 (87%) patients were admitted to the hospital, 13 (11%) were admitted to the ICU, and 4 (3.3%) died.




FIG 1 Flowchart of study participants. URT, upper respiratory tract; LRT, lower respiratory tract; LRTI, lower respiratory tract infection.

Microbiological documentation. Based on the standard composite microbiology diagnostic tests, 56% (66/118) of patients had a documented infection, while 44% (52/118) did not have any detected pathogen. A total of 39% (46/118) had a bacterium detected, 24% (28/118) a virus, and 6.8% (8/118) a virus and a bacterium. The most frequent pathogens were *H. influenzae* (16%), *S. pneumoniae* (10%), and influenza virus (10%) (see Table S1 in the supplemental material).

Based on the FilmArray PP in the LRT samples (112 sputa, 4 lung aspirates, 2 bronchoalveolar lavages), 88% (104/118) of patients had a documented pathogen, while 12% (14/118) did not. A total of 76% (90/118) patients had a bacterium detected, 57% (67/118) a virus, and 45% (53/118) a virus and a bacterium. The most frequent pathogens were *H. influenzae* (37%), *S. aureus* (25%), *S. pneumoniae* (16%), *M. catarrhalis* (12%), enterovirus (25%), and influenza virus (14%) (Table S1).

Based on the FilmArray PP in the NP swab, 82% (97/118) of patients had a documented pathogen, while 18% (21/118) did not. A total of 62% (73/118) of patients had a bacterium detected, 48% (57/118) a virus, and 13% (15/118) a virus and a bacterium. The most frequent pathogens are similar to those identified by FilmArray PP in the LRT samples (Table S1).

Compared to standard microbiology, the FilmArray PP increased the diagnostic yield of bacteria by 95% (from 39% using standard microbiology to 76% using FilmArray PP in LRT samples).

Identification of the three bacteria of interest: *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis*. Standard microbiology and FilmArray PP in LRT samples and in NP swabs identified *S. pneumoniae* in 12 (10%), 19 (16%), and 11 (9.3%), *H. influenzae* in 19 (16%), 44 (37%), and 27 (23%), and *M. catarrhalis* in none, 14 (12%), and 9 (7.6%) patients, respectively. Figure 2 shows the concordance of the three diagnostics tests for *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis*. Using FilmArray PP in LRT sample, the performance for detecting the three bacteria was similar using a positive cutoff of $>10^4$ or $>10^5$ copies/mL. Concordance between standard and molecular diagnostic tests in LRT samples was high for *S. pneumoniae* (94% of overall agreement) and lower for *H. influenzae* (79%) and *M. catarrhalis* (88%).

TABLE 1 Characteristics of study participants^{a,g}

Characteristic	No. of patients (n = 118)
Demographics	
Female sex, n (%)	43 (36)
Age (yrs), median (IQR)	71 (56, 78)
Residence in nursing home, n (%)	8 (6.8)
Current smoker, n (%)	36 (31)
Alcohol misuse, n (%)	18 (15)
Coexisting disorder, n (%)	
Any	102 (86)
Chronic obstructive pulmonary disease	34 (29)
Heart failure	24 (20)
Active neoplasia	23 (20)
Diabetes	20 (17)
Asthma	18 (15)
Neurological disorder ^b	17 (14)
Chronic renal failure ^c	17 (14)
Immunosuppressive treatment	16 (14)
Other ^d	10 (8.4)
Symptoms, n (%)	
Expectoration	82 (85)
Dyspnea	78 (76)
History of fever	66 (64)
Thoracic pain	20 (24)
Signs in emergency department	
Systolic blood pressure (mm Hg), median (IQR)	124 (110, 137)
Diastolic blood pressure (mm Hg), median (IQR)	72 (64, 81)
Heart rate (bpm), median (IQR)	90 (80, 100)
Respiratory rate (vpm), median (IQR)	21 (18, 25)
Oxygen saturation (%), median (IQR)	94 (92, 96)
Temp (°C), median (IQR)	37 (37, 38)
Abnormal lung auscultation, n (%)	82 (75)
Severity score, n (%)	
CURB-65 ≥ 2	47 (50)
qSOFA ≥ 2	17 (17)
Laboratory findings at first consultation	
Leukocyte count (g/L), median (IQR)	11 (8, 15)
CRP (mg/L), median (IQR)	74 (29, 154)
Creatinine (μmol/L), median (IQR)	86 (71, 122)
Radiology, n (%)	
Infiltrate on chest imaging ^e	88 (75)
Antibiotics administration, n (%)	
Antibiotics administrated	108 (96)
Antibiotics before LRT sample collection ^f	55 (47)
Clinical outcome, n (%)	
Hospital admission	97 (87)
Intensive care unit admission	13 (11)
Intubation	10 (8)
Death	4 (3.3)

^aIQR, interquartile range; BP, blood pressure; bpm, beat per minute; vpm, ventilation per minute; CRP, C-reactive protein; LRT, lower respiratory tract.

^bCerebrovascular disease, dementia, Parkinson.

^cKDIGO stage ≥ G3a.

^dTerminal renal failure or dialysis (n = 2), hepatic failure (n = 3), HIV infection (n = 5).

^eAll participants had a chest imaging performed (29% a CT scan, 71% only a radiography).

^f12/55 were started >48 h before sample collection.

^gMissing values: smoking status 1, CURB-65 23, qSOFA 19, fever 14, expectoration 21, dyspnea 15, thoracic pain 33, auscultation status 9, respiratory rate 19, oxygen saturation 5, fraction of inspired oxygen 3, leukocytes 5, CRP 2, urea 10, creatinine 2.




FIG 2 Venn diagrams showing the concordance between the three microbiological tests (FilmArray Pneumonia Panel plus in nasopharyngeal swab and in lower respiratory tract sample, and the composite standard microbiological tests) for *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* in the study population (n = 118).

Performance of the FilmArray in NP swabs of adults with community-acquired lower respiratory tract infection. Table 2 shows the performance of the FilmArray PP in NP swabs for the detection of *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis* in patients with community-acquired LRTI. We calculated the performance according to two reference standards. Using FilmArray PP on LRT sample as the reference standard, the PPA, NPA, positive predictive values (PPV), and negative predictive values (NPV) were, respectively, 58%, 100%, 100%, and 93% for *S. pneumoniae*, 61%, 100%, 100%, and 81% for *H. influenzae*, and 57%, 99%, 89%, and 94% for *M. catarrhalis*. Using the standard microbiology results as reference standard, the PPA, NPA, PPV, and NPV were, respectively, 58%, 96%, 64%, and 95% for *S. pneumoniae*, 74%, 87%, 52%, and 95% for *H. influenzae*, and undefinable, 92%, 0%, and 100% for *M. catarrhalis*.

Considering only patients with a respiratory sample taken before antibiotics administration (n = 55), the NPA of FilmArray PP on NP sample compared to the standard microbiology results as reference standard was not different (57%, 85%, and undefinable for *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis*, respectively).

Performance of the FilmArray in NP swabs using lower cutoff of detection. Hypothesizing that the performance of the PCR could be better with a lower positive cutoff, we performed an in-house PCR for *S. pneumoniae* and *H. influenzae* in all

TABLE 2 Performance of FilmArray Pneumonia Panel plus (FilmArray PP) in nasopharyngeal (NP) swabs for detection of *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis* in adults with community-acquired respiratory tract infections ($n = 118$ patients) compared to various reference standards: FilmArray PP on a good-quality lower respiratory tract (LRT) sample with a positive cutoff value of $>10^4$ copies/mL or with the standard microbiology results (lower respiratory tract sample culture, hemocultures, and *S. pneumoniae* urinary antigen)^a

Target organism	Reference standard	No. of positive samples								
		NP	Reference standard	PPA	NPA	OPA	LR+	LR–	PPV	NPV
<i>S. pneumoniae</i>	LRT PCR FilmArray PP	11	19	0.58	1	0.93	Infinite	0.42	1	0.93
	Standard microbiology	11	12	0.58	0.96	0.92	15.46	0.43	0.64	0.95
<i>H. influenzae</i>	LRT PCR FilmArray PP	27	44	0.61	1	0.86	Infinite	0.39	1	0.81
	Standard microbiology	27	19	0.74	0.87	0.85	5.61	0.3	0.52	0.95
<i>M. catarrhalis</i>	LRT PCR FilmArray PP	9	14	0.57	0.99	0.94	59.43	0.43	0.89	0.94
	Standard microbiology	9	0		0.92	0.92			0	1

^aPositive percent agreement (PPA), negative percent agreement (NPA), overall percent agreement (OPA), positive likelihood ratio (LR+), negative likelihood ratio (LR–), positive predictive value (PPV), negative predictive value (NPV).

respiratory samples. Considering a cutoff value of $\geq 10^2$ copies per mL on the NP swab, the PPA was slightly higher than a cutoff of $\geq 10^4$ copies per mL using FilmArray PP on LRT samples as the reference standard: 58% to 68% for *S. pneumoniae* and 61% to 77% for *H. influenzae* (Table S2). The performance was similar to that with standard microbiology as the reference standard but also to that of in-house PCR on LRT samples.

DISCUSSION

The difficulty in obtaining high-quality sputum and the long time-to-result of standard “culture-based” microbiological analyses are major limitations for timely identification of a pathogen in patients with LRTI and tailored use of antibiotics. Our data show that molecular analyses in NP swabs for identifying the most common bacterial causes of pneumonia have a high NPA and a limited PPA, suggesting their utility to promptly use targeted antibiotics in case of positive results but not their utility to withhold antibiotics in case of negative results. Lowering the detection cutoff of the molecular analysis in NP swab only slightly improves the PPA.

Few studies assessed the performance of molecular diagnostic tests on URT samples to identify the most common causes of bacterial community-acquired pneumonia. Comparison between studies is difficult, as they use different URT samples (NP, oropharyngeal [OP], or combined samples), different PCR targets, and different reference standards (PCR on LRT samples or standard microbiological tests).

We found a limited PPA of molecular analyses in NP swabs, which is concordant with the majority of previous studies. Two studies compared the performance of a syndromic molecular assay (TaqMan Array Card Technology) on a combination of URT samples (NP and OP) using the same molecular assay on high-quality sputum as reference standard in hospitalized patients with CAP: the first one, performed in the United States, found a PPA between 50 and 80% for *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis* (19), and the second one, conducted in Kenya (39% HIV-infected patients), found a PPA between 72 and 80% for *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis* (20). Three studies evaluated the performance of *lytA* RT-PCR in NP specimens for *S. pneumoniae* diagnosis using standard microbiology as reference standard in patients with CAP. In line with our study, two studies performed in Western Europe found a PPA between 44 and 72% (17, 18). However, the third study, performed in South Africa among HIV-infected adults, showed a higher PPA at 82% (15). This may be explained by a higher bacterial load in this immunocompromised population with CAP.

The excellent NPA of molecular analyses in NP swabs found in our data is in line with all previously performed studies. Using a syndromic molecular assay (TaqMan Array Card Technology) on a URT sample and high-quality sputum in hospitalized patients with CAP, a study performed in the United States and a study conducted in Kenya confirmed the high NPA ($>98\%$ and 88 to 93%, respectively) (19, 20). Using *lytA* RT-PCR in NP specimens for *S. pneumoniae* diagnosis and standard microbiology as reference standard in patients with CAP, three studies confirmed the excellent NPA: two

studies of patients in Western Europe with an NPA between 92 and 99% (17, 18) and a study performed in South Africa among HIV-infected adults, with an NPA at 92% (15).

In line with our results, a study comparing the performance of *lytA* in NP aspirate of patients admitted for CAP in Sweden found an increased PPA of the NP aspirate from 53% to 81% and a decreased NPA from 93% to 80% when lowering the detection cut-off value of the PCR (10^5 to 10^2 copies/mL) (18). However, the magnitude of the PPA increase in our study was lower, supporting the use of a cutoff at $\geq 10^4$ copies/mL in NP for *S. pneumoniae* diagnostic to keep a high NPA. (15–17). To our knowledge, our study is the first that evaluates different RT-PCR cutoffs in NP for *H. influenzae*.

Surprisingly, considering only the respiratory sample taken before antibiotics administration as the reference standard, we did not find a better NPA of FilmArray PP on NP. This can be explained by a good performance of standard microbiology, as only 12 (10%) patients received antibiotics more than 48 h before lower respiratory tract samples were collected.

Various retrospective studies suggested the utility of molecular diagnostic tests on LRT samples to deescalate or discontinue antibiotics (7–11). The high NPA of molecular tests on URT samples suggests the possibility to tailor antibiotic therapy in case of positive results, but the limited PPA does not support withdrawing antibiotics in case of negative results. In our population with CAP, we identified *S. pneumoniae*, *H. influenzae*, or *M. catarrhalis* in the NP swab of 38% of patients (45/118) who could have benefited from targeted antibiotics. However, because the first-line empirical antibiotic in patients with CAP is amoxicillin clavulanate, which is the treatment of choice of *H. influenzae* and *M. catarrhalis*, we expect an added value of a molecular test on the use of targeted antibiotics only in patients with *S. pneumoniae* (amoxicillin being the antibiotic of choice). However, only 9% (11/118) of patients had *S. pneumoniae* detected in the NP swab, limiting the potential impact of molecular tests in this CAP population.

Our study has several limitations. The first one, which is shared by all similar studies, is the absence of a gold standard for microbiological diagnostic in LRTIs, limiting the evaluation of new diagnostic tests. For this reason, we evaluated the performance of an NP swab molecular test using two reference standards, (i) standard microbiological tests (urinary antigen, LRT, and blood cultures), which are validated diagnostics tests (21), and (ii) the same molecular tests on LRT samples. This is important, as molecular tests have a higher diagnostic yield than standard microbiological tests, which may affect the NPA and falsely increase the discrepancy between culture and molecular tests (7, 8, 22, 23). Indeed, in our study, the NPA of the molecular analysis in NP swab was slightly lower using standard microbiological tests as reference standard than that using molecular analysis in LRT samples. Second, we used different PCR methods (FilmArray PP and in-house PCR) when analyzing the performance of a lower positive cutoff in NP. Nevertheless, comparing the performance of in-house PCR on NP and LRT shows similar results.

Third, our conclusions are limited to the three bacteria of interest, which are the main causes of bacterial community-acquired CAP (7). However, analyzing results of all bacteria included in the FilmArray Pneumonia plus panel (i.e., Gram-negative bacteria usually found in hospital-acquired infection) does not make sense in this population with community-acquired LRTI. Some studies also found a significant quantity of *Staphylococcus aureus* isolates and Gram-negative enteric bacilli in patients with CAP (24). However, these bacteria are described more frequently in severe pneumonia (25), in which withholding antibiotics is not an option.

Fourth, our small sample size and a selection bias of patients with good-quality sputa limit the generalizability of our conclusions. Indeed, we excluded 55% of patients because they did not reach the predefined criteria of sputum quality. As we tested a new diagnostic method, it was important to use the best possible reference standard. Using these inclusion criteria, 95% of patients received antibiotics, representing a population with LRTIs in which limitation of antibiotics is a challenge. However, we need

more studies on this topic to evaluate the performance of other respiratory samples, such as low-quality sputa and oral and oropharyngeal swabs.

Finally, the optimal choice of URT sampling is still unknown, and we used only NP swabs. Previously cited studies comparing different URT and LRT samples showed an advantage of the NP swabs for identifying colonization by *S. pneumoniae*, no difference between NP and OP for *H. influenzae*, and an advantage of OP for *M. catarrhalis* (26). In our study, we chose the NP sample as they are already used in routine care for other molecular diagnoses.

Another limitation is that we used FilmArray PP, which is not validated for use in URT samples.

Conclusion. Our data showed that FilmArray PP in NP swabs for identifying the most common etiologies of community-acquired LRTI has a limited PPA, preventing its use for withholding antibiotics, but an excellent NPA, suggesting its use for targeted antibiotics in case of positive result, which is in line with the majority of previous studies. The real-life impact of rapid syndromic molecular testing should be tested in a randomized controlled trial.

MATERIALS AND METHODS

Study design and participants. This is a retrospective study of adult patients (≥ 18 years) who attended the University Hospital of Lausanne, a tertiary care center in Switzerland, and who had available NP swab and LRT sample (sputa, lung aspirates, bronchoalveolar lavage) during two periods: February to May 2019 (phase 1) and November 2019 to August 2020 (phase 2). We chose these periods because of the systematic use of NP swab in patients with respiratory symptoms during the flu season and the COVID-19 pandemic.

Exclusion criteria were absence of LRTI (defined as an acute illness of ≤ 21 days, with cough as the main symptom, with ≥ 1 other lower respiratory tract symptom [sputum production, dyspnea, and/or chest discomfort/pain], and no alternative explanation) (27), presence of chronic lung disease (bronchiectasis, cystic fibrosis), hospitalization in an acute care hospital in the last 3 months, a low-quality sputum or lung aspirate (quality criteria defined as ≥ 25 neutrophils and < 10 epithelial cells per low-power field) (28), upper and lower respiratory tract samples collected with a delay of ≥ 24 h, sample collection more than 48 h after admission, and refusal to participate in the study.

Patients' demographics, comorbidities, symptoms, vital signs, radiology reports (chest X-rays or CT scans), and laboratory test results performed at admission were retrospectively recorded using a standardized electronic case report form in Research Electronic Data Capture (REDCap software). A radiologist reviewed chest X-rays that had no report available.

Respiratory samples and microbiological analyses. All respiratory samples were collected during routine care. Nurses performed the NP swabs (COPAN UTM with 3 mL of medium) according to standard institutional guidelines. If a patient had several LRT samples available, we chose first the bronchoalveolar lavage, then the lung aspirate, and finally the sputum. All respiratory samples were kept at -80°C within 24 h of collection. LRT samples were liquefied using a solution containing dithiothreitol to homogenize the specimens and improve the reliability of molecular tests, as described previously (29–31).

The NP swabs and LRT samples were tested with the FilmArray PP according to the manufacturer's instructions. Results are expressed as semiquantitative results ($< 10^{3.5}$: negative; 10^4 , 10^5 , 10^6 , or $\geq 10^7$: positive) in DNA copies per mL for bacteria and as qualitative results (presence/absence) for atypical bacteria and viruses. We also tested all specimens with in-house real-time PCR on the automated molecular diagnostic platform of the Institute of Microbiology for (i) *S. pneumoniae* and (ii) *H. influenzae* using, respectively, *lytA* and *rdB* as targeted genes (15, 29).

Statistical analyses. We calculated the PPA, NPA, overall percent agreement (OPA) (32), positive and negative likelihood ratio, and positive and negative predictive values (PPV and NPV) of the FilmArray PP in NP swabs for the community-acquired respiratory bacteria of interest (*S. pneumoniae*, *H. influenzae*, *M. catarrhalis*) using two reference standards: (i) FilmArray PP in lower respiratory tract sample and (ii) a composite of standard microbiological tests (blood culture, LRT sample culture [considered positive if $\geq 10^5$ CFU/mL in sputum {7, 33}, $\geq 10^4$ CFU/mL in lung aspirates, or $\geq 10^3$ in bronchoalveolar lavage {34}], and *S. pneumoniae* urinary antigen).

We also calculated the performance of the FilmArray PP in NP swabs in a subgroup analysis: patients without prior use of antibiotics (to avoid the potential impact of antibiotics on cultures and a subsequent underevaluation of the specificity of the FilmArray PP in NP swabs).

Data were analyzed using RStudio software, version 1.3.1056 (Integrated Development Environment for R, RStudio, PBC, Boston, MA).

Ethical approval. All included patients signed a general consent form for research or provided written informed consent retrospectively. The study was accepted by the ethical commission of Canton de Vaud (Project-ID 2019-00961).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.5 MB.

ACKNOWLEDGMENTS

We thank Marie-Anne Page, Martin Delaloye, Timothée Vesin, Le Roy Didier, Marc-Antoine Perrrenoud, Gregory Gonzalez, Zahera Naseri, Michael Metrailler, and the entire Laboratory of Molecular Diagnostics and Mycobacteria of the Institute of Microbiology.

This work was supported by an academic award of the Leenaards Foundation (to N.B.-B.) and Eurostars (E! 113595, to N.B.-B.). bioMérieux gave FilmArray Pneumonia Plus panel kits and torch free of charge for the study purposes. The funding bodies had no role in the design of the study, in collection, analysis, interpretation of data, or in writing the manuscript.

We declare no competing interests.

Y.D., K.J., O.O., N.B.-B.: study conception, study design, study performance, study management, data analysis, data interpretation, and manuscript writing. T.B.: data analysis, data interpretation, and critical review of the manuscript. D.C.R.: chest X-ray interpretation, data interpretation, and critical review of the manuscript.

REFERENCES

1. Federal Office of Public Health and Federal Food Safety and Veterinary Office. 2020. Swiss antibiotic resistance report 2020. Usage of antibiotics and occurrence of antibiotic resistance in Switzerland. Federal Office of Public Health and Federal Food Safety and Veterinary Office, Bern, Switzerland.
2. Carugati M, Aliberti S, Sotgiu G, Blasi F, Gori A, Menendez R, Encheva M, Gallego M, Leuschner P, Ruiz-Buitrago S, Battaglia S, Fantini R, Pascual-Guardia S, Marin-Corral J, Restrepo MI, GLIMP Collaborators. 2020. Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. *Eur J Clin Microbiol Infect Dis* 39:1513–1525. <https://doi.org/10.1007/s10096-020-03870-3>.
3. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, Reed C, Grijalva CG, Anderson EJ, Courtney DM, Chappell JD, Qi C, Hart EM, Carroll F, Trabue C, Donnelly HK, Williams DJ, Zhu Y, Arnold SR, Ampofo K, Waterer GW, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, McCullers JA, Pavia AT, Edwards KM, Finelli L, CDC EPIC Study Team. 2015. Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med* 373:415–427. <https://doi.org/10.1056/NEJMoa1500245>.
4. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Read R, Verheij TJM, Joint Taskforce of the European Respiratory Society and European Society for Clinical Microbiology and Infectious Diseases. 2011. Guidelines for the management of adult lower respiratory tract infections—full version. *Clin Microbiol Infect* 17 Suppl 6:E1–E59. <https://doi.org/10.1111/j.1469-0691.2011.03672.x>.
5. Bartlett JG. 2011. Diagnostic tests for agents of community-acquired pneumonia. *Clin Infect Dis* 52:S296–S304. <https://doi.org/10.1093/cid/cir045>.
6. Poole S, Clark TW. 2020. Rapid syndromic molecular testing in pneumonia: the current landscape and future potential. *J Infect* 80:1–7. <https://doi.org/10.1016/j.jinf.2019.11.021>.
7. Gadsby NJ, Russell CD, McHugh MP, Mark H, Conway Morris A, Laurenson IF, Hill AT, Templeton KE. 2016. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. *Clin Infect Dis* 62:817–823. <https://doi.org/10.1093/cid/civ1214>.
8. Monard C, Pehlivan J, Auger G, Alviset S, Tran Dinh A, Duquaire P, Gastli N, d’Humières C, Maamar A, Boibieux A, Baldeyrou M, Loubinoux J, Dauwalder O, Cattoir V, Armand-Lefèvre L, Kernés S, Becker A, Charpentier J, Textoris J, Gustave C-A, Destras G, Vandenesch F, Lina B, Casalegno JS, Lejeune M, Montravers P, Poyart C, Tête H, Timsit J-F, Uberti T, the ADAPT study group. 2020. Multicenter evaluation of a syndromic rapid multiplex PCR test for early adaptation of antimicrobial therapy in adult patients with pneumonia. *Crit Care* 24:434. <https://doi.org/10.1186/s13054-020-03114-y>.
9. Buchan BW, Windham S, Balada-Llasat J-M, Leber A, Harrington A, Relich R, Murphy C, Dien Bard J, Naccache S, Ronen S, Hopp A, Mahmutoglu D, Faron ML, Ledebauer NA, Carroll A, Stone H, Akerele O, Everhart K, Bonwit A, Kwong C, Buckner R, Warren D, Fowler R, Chandrasekaran S, Huse H, Campeau S, Humphries R, Graue C, Huang A. 2020. Practical comparison of the BioFire FilmArray pneumonia panel to routine diagnostic methods and potential impact on antimicrobial stewardship in adult hospitalized patients with lower respiratory tract infections. *J Clin Microbiol* 58. <https://doi.org/10.1128/JCM.00135-20>.
10. Jones NK, Conway Morris A, Curran MD, Parmar S, Sule O, Enoch DA, Aliyu SH, Zhang H, Jalal H, Navapurkar V, Murphy ME. 2020. Evaluating the use of a 22-pathogen TaqMan array card for rapid diagnosis of respiratory pathogens in intensive care. *J Med Microbiol* 69:971–978. <https://doi.org/10.1099/jmm.0.001218>.
11. Lee SH, Ruan S-Y, Pan S-C, Lee T-F, Chien J-Y, Hsueh P-R. 2019. Performance of a multiplex PCR pneumonia panel for the identification of respiratory pathogens and the main determinants of resistance from the lower respiratory tract specimens of adult patients in intensive care units. *J Microbiol Immunol Infect* 52:920–928. <https://doi.org/10.1016/j.jmii.2019.10.009>.
12. Holter JC, Müller F, Bjørang O, Samdal HH, Marthinsen JB, Jenum PA, Ueland T, Frøland SS, Aukrust P, Husebye E, Heggelund L. 2015. Etiology of community-acquired pneumonia and diagnostic yields of microbiological methods: a 3-year prospective study in Norway. *BMC Infect Dis* 15:64. <https://doi.org/10.1186/s12879-015-0803-5>.
13. Goldblatt D, O’Brien KL. 2018. Pneumococcal infections. In Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J (ed), Harrison’s principles of internal medicine, 20th ed. McGraw-Hill Education, New York, NY.
14. Murdoch DR. 2016. How recent advances in molecular tests could impact the diagnosis of pneumonia. *Expert Rev Mol Diagn* 16:533–540. <https://doi.org/10.1586/14737159.2016.1156536>.
15. Albrich WC, Madhi SA, Adrian PV, van Niekerk N, Marelets T, Cutland C, Wong M, Khoosal M, Karstaedt A, Zhao P, Deatly A, Sidhu M, Jansen KU, Klugman KP. 2012. Use of a rapid test of pneumococcal colonization density to diagnose pneumococcal pneumonia. *Clin Infect Dis* 54:601–609. <https://doi.org/10.1093/cid/cir859>.
16. Gillis HD, Lang ALS, ElSherif M, Martin I, Hatchette TF, McNeil SA, LeBlanc JJ. 2017. Assessing the diagnostic accuracy of PCR-based detection of Streptococcus pneumoniae from nasopharyngeal swabs collected for viral studies in Canadian adults hospitalised with community-acquired pneumonia: a Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research (CIRN) study. *BMJ Open* 7:e15008. <https://doi.org/10.1136/bmjopen-2016-015008>.
17. Saukkoripi A, Palmu AA, Pascal T, Verlant V, Hausdorff WP, Jokinen J. 2018. *lytA* quantitative PCR on sputum and nasopharyngeal swab samples for detection of pneumococcal pneumonia among the elderly. *J Clin Microbiol* 56. <https://doi.org/10.1128/JCM.01231-17>.
18. Strålin K, Herrmann B, Abdeldaim G, Olcén P, Holmberg H, Mölling P. 2014. Comparison of sputum and nasopharyngeal aspirate samples and of the PCR gene targets *lytA* and *Spn9802* for quantitative PCR for rapid detection of pneumococcal pneumonia. *J Clin Microbiol* 52:83–89. <https://doi.org/10.1128/JCM.01742-13>.
19. Wolff BJ, Bramley AM, Thurman KA, Whitney CG, Whitaker B, Self WH, Arnold SR, Trabue C, Wunderink RG, McCullers J, Edwards KM, Jain S, Winchell JM. 2017. Improved detection of respiratory pathogens by use of high-quality sputum with TaqMan array card technology. *J Clin Microbiol* 55:110–121. <https://doi.org/10.1128/JCM.01805-16>.

20. Nyawanda BO, Njuguna HN, Onyango CO, Makokha C, Lidechi S, Fields B, Winchell JM, Katieno JS, Nyaundi J, Ade F, Emukule GO, Mott JA, Otieno N, Widdowson M-A, Chaves SS. 2019. Comparison of respiratory pathogen yields from nasopharyngeal/oropharyngeal swabs and sputum specimens collected from hospitalized adults in rural Western Kenya. *Sci Rep* 9: 11237. <https://doi.org/10.1038/s41598-019-47713-4>.
21. Hanson KE, Azar MM, Banerjee R, Chou A, Colgrove RC, Ginocchio CC, Hayden MK, Holodiny M, Jain S, Koo S, Levy J, Timbrook TT, Caliendo AM. 2020. Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's diagnostics committee. *Clin Infect Dis* 71:2744–2751. <https://doi.org/10.1093/cid/ciaa508>.
22. Baudel J-L, Tankovic J, Dahoumane R, Carrat F, Galbois A, Ait-Oufella H, Offenstadt G, Guidet B, Maury E. 2014. Multiplex PCR performed of bronchoalveolar lavage fluid increases pathogen identification rate in critically ill patients with pneumonia: a pilot study. *Ann Intensive Care* 4:35. <https://doi.org/10.1186/s13613-014-0035-7>.
23. Murphy CN, Fowler R, Balada-Llasat JM, Carroll A, Stone H, Akerele O, Buchan B, Windham S, Hopp A, Ronen S, Relich RF, Buckner R, Warren DA, Humphries R, Campeau S, Huse H, Chandrasekaran S, Leber A, Everhart K, Harrington A, Kwong C, Bonwit A, Dien Bard J, Naccache S, Zimmerman C, Jones B, Rindlisbacher C, Buccambuso M, Clark A, Rogatcheva M, Graue C, Bourzac KM. 2020. Multicenter evaluation of the BioFire FilmArray pneumonia/pneumonia plus panel for detection and quantification of agents of lower respiratory tract infection. *J Clin Microbiol* 58. <https://doi.org/10.1128/JCM.00128-20>.
24. Torres A, Blasi F, Peetermans WE, Vieg G, Welte T. 2014. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. *Eur J Clin Microbiol Infect Dis* 33:1065–1079. <https://doi.org/10.1007/s10096-014-2067-1>.
25. Woodhead M. 2002. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. *Eur Respir J Suppl* 36:20s–27s. <https://doi.org/10.1183/09031936.02.00702002>.
26. Lieberman D, Shleyfer E, Castel H, Terry A, Harman-Boehm I, Delgado J, Peled N, Lieberman D. 2006. Nasopharyngeal versus oropharyngeal sampling for isolation of potential respiratory pathogens in adults. *J Clin Microbiol* 44:525–528. <https://doi.org/10.1128/JCM.44.2.525-528.2006>.
27. Ieven M, Coenen S, Loens K, Lammens C, Coenjaerts F, Vanderstraeten A, Henriques-Normark B, Crook D, Huygen K, Butler CC, Verheij TJM, Little P, Zlateva K, van Loon A, Claas ECJ, Goossens H, GRACE consortium. 2018. Aetiology of lower respiratory tract infection in adults in primary care: a prospective study in 11 European countries. *Clin Microbiol Infect* 24: 1158–1163. <https://doi.org/10.1016/j.cmi.2018.02.004>.
28. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. 1977. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. *J Clin Microbiol* 6:396–399. <https://doi.org/10.1128/jcm.6.4.396-399.1977>.
29. Greub G, Sahli R, Brouillet R, Jatton K. 2016. Ten years of R&D and full automation in molecular diagnosis. *Future Microbiol* 11:403–425. <https://doi.org/10.2217/fmb.15.152>.
30. Opota O, Brouillet R, Greub G, Jatton K. 2017. Methods for real-time PCR-based diagnosis of *Chlamydia pneumoniae*, *Chlamydia psittaci*, and *Chlamydia abortus* infections in an opened molecular diagnostic platform. *Methods Mol Biol* 1616:171–181. https://doi.org/10.1007/978-1-4939-7037-7_11.
31. Opota O, Zakham F, Mazza-Stalder J, Nicod L, Greub G, Jatton K. 2019. Added value of Xpert MTB/RIF ultra for diagnosis of pulmonary tuberculosis in a low-prevalence setting. *J Clin Microbiol* 57. <https://doi.org/10.1128/JCM.01717-18>.
32. Center for Devices and Radiological Health. 2020. Statistical guidance on reporting results from studies evaluating diagnostic tests - guidance for industry and FDA staff. US Food and Drug Administration, Silver Spring, MD.
33. Thorsteinsson SB, Musher DM, Fagan T. 1975. The diagnostic value of sputum culture in acute pneumonia. *JAMA* 233:894–895. <https://doi.org/10.1001/jama.1975.03260080056024>.
34. Cantral DE, Tape TG, Reed EC, Spurzem JR, Rennard SI, Thompson AB. 1993. Quantitative culture of bronchoalveolar lavage fluid for the diagnosis of bacterial pneumonia. *Am J Med* 95:601–607. [https://doi.org/10.1016/0002-9343\(93\)90356-T](https://doi.org/10.1016/0002-9343(93)90356-T).